請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/76788完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 林峯輝(Feng-Huei Lin) | |
| dc.contributor.author | Jung-Feng Lin | en |
| dc.contributor.author | 林榮峰 | zh_TW |
| dc.date.accessioned | 2021-07-10T21:36:59Z | - |
| dc.date.available | 2021-07-10T21:36:59Z | - |
| dc.date.copyright | 2020-09-23 | |
| dc.date.issued | 2020 | |
| dc.date.submitted | 2020-08-20 | |
| dc.identifier.citation | [1] J.A. Sargent, S.R. Acchiardo, Iron requirements in hemodialysis, Blood purification 22(1) (2004) 112-123. [2] L. Gotloib, D. Silverberg, R. Fudin, A. Shostak, Iron deficiency is a common cause of anemia in chronic kidney disease and can often be corrected with intravenous iron, Journal of nephrology 19(2) (2006) 161. [3] T. Tsukamoto, T. Matsubara, Y. Akashi, M. Kondo, M. Yanagita, Annual iron loss associated with hemodialysis, American Journal of Nephrology 43(1) (2016) 32-38. [4] K. Pantelias, E. Grapsa, Management of Anemia on Hemodialysis, Hemodialysis, IntechOpen2013. [5] G. Rostoker, N.D. Vaziri, S. Fishbane, Iatrogenic Iron Overload in Dialysis Patients at the Beginning of the 21st Century, Drugs 76(7) (2016) 741-757. [6] C.E. Lankhorst, J.B. Wish, Anemia in renal disease: diagnosis and management, Blood reviews 24(1) (2010) 39-47. [7] H. Ludwig, K. Strasser, Symptomatology of anemia, Seminars in Oncology 28 (2001) 7-14. [8] J. Anderson, C. Fitzgerald, Iron: an essential nutrient, Food and nutrition series. Health; no. 9.356 (1989). [9] S. Varma, W. Baz, E. Badine, F. Nakhl, H. McMullen, J. Nicastro, F. Forte, T. Terjanian, Q. Dai, Need for parenteral iron therapy after bariatric surgery, Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery 4(6) (2008) 715-9. [10] S. Fishbane, G.L. Frei, J. Maesaka, Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation, American journal of kidney diseases : the official journal of the National Kidney Foundation 26(1) (1995) 41-6. [11] C. Charytan, M.H. Schwenk, M.M. Al-Saloum, B.S. Spinowitz, Safety of iron sucrose in hemodialysis patients intolerant to other parenteral iron products, Nephron Clin Pract 96(2) (2004) c63-6. [12] P. Kaye, K. Abdulla, J. Wood, P. James, S. Foley, K. Ragunath, J. Atherton, Iron-induced mucosal pathology of the upper gastrointestinal tract: a common finding in patients on oral iron therapy, Histopathology 53(3) (2008) 311-317. [13] D.B. Van Wyck, Efficacy and adverse effects of oral iron supplements, Seminars in Dialysis, Wiley Online Library, 1999, pp. 235-236. [14] W.-L. He, Y. Feng, X.-L. Li, X.-E. Yang, Comparison of iron uptake from reduced iron powder and FeSO4 using the Caco-2 cell model: effects of ascorbic acid, phytic acid, and pH, Journal of agricultural and food chemistry 56(8) (2008) 2637-2642. [15] P.V. Sacks, D.N. Houchin, Comparative bioavailability of elemental iron powders for repair of iron deficiency anemia in rats. Studies of efficacy and toxicity of carbonyl iron, The American Journal of Clinical Nutrition 31(4) (1978) 566-571. [16] J.-F. Lin, C.-C. Wu, Y.-J. Liao, S. Jakfar, Z.-B. Tang, J.-K. Chen, F.-H. Lin, In vitro and In vivo evaluations of mesoporous iron particles for iron bioavailability, International journal of molecular sciences 20(21) (2019) 5291. [17] L.N. Chan, L.A. Mike, The Science and Practice of Micronutrient Supplementations in Nutritional Anemia: An Evidence‐Based Review, Journal of Parenteral and Enteral Nutrition 38(6) (2014) 656-672. [18] D.D. Miller, Minerals, Fennema's Food Chemistry, CRC Press2007, pp. 535-582. [19] S. Lopez-Giacoman, M. Madero, Biomarkers in chronic kidney disease, from kidney function to kidney damage, World journal of nephrology 4(1) (2015) 57. [20] K. Nashar, B.M. Egan, Relationship between chronic kidney disease and metabolic syndrome: current perspectives, Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 7 (2014) 421. [21] V. Cachofeiro, M. Goicochea, S.G. De Vinuesa, P. Oubiña, V. Lahera, J. Luño, Oxidative stress and inflammation, a link between chronic kidney disease and cardiovascular disease: New strategies to prevent cardiovascular risk in chronic kidney disease, Kidney International 74 (2008) S4-S9. [22] P.J. Ratcliffe, Molecular biology of erythropoietin, Kidney international 44(4) (1993) 887-904. [23] J.L. Babitt, H.Y. Lin, Mechanisms of Anemia in CKD, Journal of the American Society of Nephrology 23(10) (2012) 1631-1634. [24] A.M. Shaman, S.R. Kowalski, Hyperphosphatemia management in patients with chronic kidney disease, Saudi Pharmaceutical Journal 24(4) (2016) 494-505. [25] Y.C. Hou, C.L. Lu, K.C. Lu, Mineral bone disorders in chronic kidney disease, Nephrology 23 (2018) 88-94. [26] R. Thomas, A. Kanso, J.R. Sedor, Chronic kidney disease and its complications, Prim Care 35(2) (2008) 329-vii. [27] G. Rishi, V.N. Subramaniam, The relationship between systemic iron homeostasis and erythropoiesis, Bioscience Reports 37(6) (2017). [28] R.D. Graham, J.C. Stangoulis, Trace element uptake and distribution in plants, The Journal of nutrition 133(5) (2003) 1502S-1505S. [29] K.A. Duck, J.R. Connor, Iron uptake and transport across physiological barriers, Biometals 29(4) (2016) 573-591. [30] S. Gulec, G.J. Anderson, J.F. Collins, Mechanistic and regulatory aspects of intestinal iron absorption, Am J Physiol Gastrointest Liver Physiol 307(4) (2014) G397-G409. [31] D.J.R. Lane, D.-H. Bae, A.M. Merlot, S. Sahni, D.R. Richardson, Duodenal cytochrome b (DCYTB) in iron metabolism: an update on function and regulation, Nutrients 7(4) (2015) 2274-2296. [32] S. Rizvi, R.E. Schoen, Supplementation with oral vs. intravenous iron for anemia with IBD or gastrointestinal bleeding: is oral iron getting a bad rap?, Am J Gastroenterol 106(11) (2011) 1872-9. [33] K. Nakanishi, Pore structure control of silica gels based on phaseseparation, Journal of Porous Materials 4(2) (1997) 67-112. [34] F. Hoffmann, M. Cornelius, J. Morell, M. Fröba, Silica‐based mesoporous organic–inorganic hybrid materials, Angewandte Chemie International Edition 45(20) (2006) 3216-3251. [35] N. Masoumifard, R. Guillet‐Nicolas, F. Kleitz, Synthesis of engineered zeolitic materials: from classical zeolites to hierarchical core–shell materials, Advanced Materials 30(16) (2018) 1704439. [36] D. Gu, F. Schüth, Synthesis of non-siliceous mesoporous oxides, Chemical Society Reviews 43(1) (2014) 313-344. [37] A. Pattanayak, A. Subramanian, Impact of porogens on the pore characteristics of zirconia particles made by polymer‐induced colloid aggregation, International Journal of Applied Ceramic Technology 8(1) (2011) 94-111. [38] T. Udenni Gunathilake, Y.C. Ching, K.Y. Ching, C.H. Chuah, L.C. Abdullah, Biomedical and microbiological applications of bio-based porous materials: A review, Polymers 9(5) (2017) 160. [39] G. Ahuja, K. Pathak, Porous carriers for controlled/modulated drug delivery, Indian journal of pharmaceutical sciences 71(6) (2009) 599. [40] Z. Qian, D. Radke, W. Jia, M. Tahtinen, G. Wang, F. Zhao, Bioengineering Scaffolds for Regenerative Engineering, (2019). [41] J. Suwanprateeb, F. Thammarakcharoen, P. Phanphiriya, W. Chokevivat, W. Suvannapruk, B. Chernchujit, Preparation and characterizations of antibiotic impregnated microporous nano-hydroxyapatite for osteomyelitis treatment, Biomedical Engineering: Applications, Basis and Communications 26(03) (2014) 1450041. [42] J.-W. Rao, L.-Q. Ouyang, X.-l. Jia, D.-P. Quan, Y.-B. Xu, The fabrication and characterization of 3D porous sericin/fibroin blended scaffolds, Biomedical Engineering: Applications, Basis and Communications 23(01) (2011) 1-12. [43] D. Silvestri, C. Cristallini, M. Domenichini, M. Gagliardi, P. Giusti, Non conventional surface functionalization of porous poly-ε-caprolactone scaffolds using bioactive molecularly imprinted nanospheres, Biomedical Engineering: Applications, Basis and Communications 22(05) (2010) 337-349. [44] S.S. Silva, E.M. Fernandes, S. Pina, J. Silva-Correia, S. Vieira, J.M. Oliveira, R.L. Reis, 2.11 Polymers of Biological Origin☆, in: P. Ducheyne (Ed.), Comprehensive Biomaterials II, Elsevier, Oxford, 2017, pp. 228-252. [45] L. Yahia, N. Chirani, L. Gritsch, F. Motta, C. Natta, History and Applications of Hydrogels. iMedPub Journals 4, (2015). [46] N.H. Ahmad, S. Mustafa, Y.B. Che Man, Microbial polysaccharides and their modification approaches: a review, International Journal of Food Properties 18(2) (2015) 332-347. [47] A.V. Nair, M. Raman, M. Doble, Chapter 13 - Polysaccharide-based hydrogels for targeted drug delivery, in: A.-M. Holban, A.M. Grumezescu (Eds.), Materials for Biomedical Engineering, Elsevier2019, pp. 343-382. [48] D. Semnani, Geometrical characterization of electrospun nanofibers, Electrospun Nanofibers, Elsevier2017, pp. 151-180. [49] H. Giesche, Mercury porosimetry: a general (practical) overview, Particle particle systems characterization 23(1) (2006) 9-19. [50] R.B. van Breemen, Y. Li, Caco-2 cell permeability assays to measure drug absorption, Expert opinion on drug metabolism toxicology 1(2) (2005) 175-85. [51] M.N. García-Casal, I. Leets, M. Layrisse, β-carotene and inhibitors of iron absorption modify iron uptake by Caco-2 cells, The Journal of nutrition 130(1) (2000) 5-9. [52] R.P. Glahn, O.A. Lee, A. Yeung, M.I. Goldman, D.D. Miller, Caco-2 cell ferritin formation predicts nonradiolabeled food iron availability in an in vitro digestion/Caco-2 cell culture model, The Journal of nutrition 128(9) (1998) 1555-1561. [53] R.P. Glahn, M. Rassier, M.I. Goldman, O.A. Lee, J. Cha, A comparison of iron availability from commercial iron preparations using an in vitro digestion/Caco-2 cell culture model, The Journal of nutritional biochemistry 11(2) (2000) 62-68. [54] J.M. Becker, G.A. Caldwell, E.A. Zachgo, Exercise 13 - Protein Assays, in: J.M. Becker, G.A. Caldwell, E.A. Zachgo (Eds.), Biotechnology (Second Edition), Academic Press, San Diego, 1996, pp. 119-124. [55] T. Jansen, R. Wallin, A practical guide to ISO 10993-12: sample preparation and reference materials, MEDICAL DEVICE AND DIAGNOSTIC INDUSTRY 20 (1998) 61-62. [56] I. ISO, 10993-5: 2009, Biological evaluation of medical devices–Part 5 (1999). [57] H. Tominaga, M. Ishiyama, F. Ohseto, K. Sasamoto, T. Hamamoto, K. Suzuki, M. Watanabe, A water-soluble tetrazolium salt useful for colorimetric cell viability assay, Analytical Communications 36(2) (1999) 47-50. [58] N.-S. Shaw, Y.-H. Liu, Bioavailability of iron from purple laver (Porphyra spp.) estimated in a rat hemoglobin regeneration bioassay, Journal of agricultural and food chemistry 48(5) (2000) 1734-1737. [59] A.W. Mahoney, C.C. VanOrden, D.G. Hendricks, Efficiency of converting food iron into hemoglobin by the anemic rat, Annals of Nutrition and Metabolism 17(4) (1974) 223-230. [60] K.S. Sing, Reporting physisorption data for gas/solid systems with special reference to the determination of surface area and porosity (Recommendations 1984), Pure and applied chemistry 57(4) (1985) 603-619. [61] M. Arredondo, V. Salvat, F. Pizarro, M. Olivares, Smaller iron particle size improves bioavailability of hydrogen-reduced iron–fortified bread, Nutrition research 26(5) (2006) 235-239. [62] M.A. Arredondo Olguín, V. Salvat, F. Pizarro Aguirre, M. Olivares Grohnert, Smaller iron particle size improves bioavailability of hydrogen-reduced iron-fortified bread, (2006). [63] Swain, J. H., Newman, S. M., Hunt, J. R. (2003). Bioavailability of elemental iron powders to rats is less than bakery-grade ferrous sulfate and predicted by iron solubility and particle surface area. The Journal of nutrition, 133(11), 3546-3552. [64] Lynch, Bothwell, L. Campbell, A comparison of physical properties, screening procedures and a human efficacy trial for predicting the bioavailability of commercial elemental iron powders used for food fortification, International journal for vitamin and nutrition research 77(2) (2007) 107-124. [65] Y. Kohgo, K. Ikuta, T. Ohtake, Y. Torimoto, J. Kato, Body iron metabolism and pathophysiology of iron overload, International journal of hematology 88(1) (2008) 7-15. [66] K.-C. Yang, C.-C. Wang, C.-C. Wu, T.-Y. Hung, H.-C. Chang, H.-K. Chang, F.-H. Lin, Acute and subacute oral toxicity tests of sintered dicalcium pyrophosphate on ovariectomized rats for osteoporosis treatment, Biomedical Engineering: Applications, Basis and Communications 22(03)(2010) 169-176. | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/76788 | - |
| dc.description.abstract | 失血是導致與透析有關的鐵缺乏症的主要因素，長期失血將導致缺鐵性貧血。 對於許多患者來說，口服鐵劑是一線治療。元素鐵是一種100% 鐵質來源，可減少每日服藥次數。本研究利用合成的多孔性鐵粒子（Porous Iron Particle, PIP）用於治療缺鐵性貧血的病患。使用改良的硼氫化物還原法成功地合成了多孔鐵顆粒。該方法能夠顯著提高孔徑和表面積，從而增加溶解度。通過Caco-2 細胞模型體外測量其生物利用度，通過監測Caco-2細胞中鐵蛋白的含量來檢查多孔性鐵粒子的體外生物利用度。由於多孔性鐵粒子孔徑提高增加其表面，造成PIP 的鐵蛋白吸收量明顯高於多孔性較差的商業鐵顆粒( p<0.05)。在缺鐵性貧血大鼠中的生物利用度相比，通過測量體重與血紅素相關的參數來檢查多孔性鐵粒子的體內生物利用度。最後，與長期貧血對照組相比，補充多孔性鐵粒子的貧血大鼠的平均血紅蛋白含量和血紅蛋白再生效率明顯更高(p<0.01)。因此，在缺鐵性貧血中，多孔性鐵粒子可以有效恢復血紅素。在為期兩周的口服毒性試驗中，多孔性鐵粒子對大鼠生理學及組織病理學無明顯毒性且不會造成肝臟毒性。因此，在缺鐵性貧血中多孔性鐵粒子可以有效恢復血紅素。 | zh_TW |
| dc.description.abstract | Blood loss is the main factor leading to iron deficiency related to hemodialysis. Long-term blood loss will lead to iron deficiency anemia. For many patients, oral iron is the first-line treatment. Elemental iron is a 100% iron source that reduces the number of daily medications. In this study, synthetic porous iron particles (PIP) were used to treat patients with iron deficiency anemia. Porous iron particles were successfully synthesized using a modified borohydride reduction method. This method can significantly increase pore size and surface area, thereby increasing solubility. The bioavailability of Caco-2 cell model was measured in vitro, and the in vitro bioavailability of porous iron particles was checked by monitoring the content of ferritin in Caco-2 cells. As the pore size of the porous iron particles increases and the surface is increased, the ferritin absorption of PIP is significantly higher than that of commercial iron particles with poor porosity (p<0.05). Compared with the bioavailability in iron-deficiency anemia rats, the in vivo bioavailability of porous iron particles was examined by measuring the parameters related to body weight and hemoglobin. Finally, compared with the anemia control group, the average hemoglobin content and hemoglobin regeneration efficiency of anemia rats supplemented with porous iron particles were significantly higher (p<0.01). Therefore, in iron-deficiency anemia, porous iron particles can effectively restore hemoglobin. In the two-week oral toxicity test, porous iron particles were not significantly toxic to rat physiology and histopathology and did not cause liver toxicity. Therefore, porous iron particles can effectively restore hemoglobin in iron-deficiency anemia. | en |
| dc.description.provenance | Made available in DSpace on 2021-07-10T21:36:59Z (GMT). No. of bitstreams: 1 U0001-1808202014042300.pdf: 6395636 bytes, checksum: 65cd0b77a61ee47d0ed749b8b8f86e00 (MD5) Previous issue date: 2020 | en |
| dc.description.tableofcontents | 口試委員會審定書 ......................................................... i 誌謝 ............................................................ ii 中文摘要 ............................................................. iii Abstract ............................................................... iv CONTENT .............................................................. v LIST OF FIGURES ....................................................... vii LIST OF TABLES ........................................................ viii LIST OF MATH FORMULAS .................................................. ix ABBREVIATIONS .......................................................... x Chapter 1 Introduction ................................................. 1 1.1 Anemia of hemodialysis patient ..................................... 1 1.1.1 Iron deficiency Anemia ........................................... 2 1.1.2 Current Treatment in Iron Deficiency Anemia .................... 4 1.2 Object of study .................................................... 7 Chapter 2 Theoretical Basis ............................................ 8 2.1 Chronic kidney disease (CKD) ....................................... 8 2.1.1 Complication ..................................................... 9 2.2 Role of iron ....................................................... 11 2.2.1 Iron absorption in human ......................................... 12 2.3 Preparation of Porous particle ..................................... 13 2.3.1 Porogen........................................................... 14 2.3.2 Dextran .......................................................... 16 Chapter 3 Materials and Methods ........................................ 17 3.1 Materials .......................................................... 17 3.1.1 Chemicals and reagents ........................................... 17 3.1.2 Instruments ...................................................... 19 3.2 Flow chart ......................................................... 20 3.4 Characterization of porous iron particles performance .............. 22 3.4.2 Transmission Electron Microscopy (TEM) ....................... 23 3.4.3 BET .............................................................. 23 3.4.4 Porosity .......................................................... 24 3.4.5 Dynamic Light Scattering (DLS) .................................... 24 3.5 In vitro study ...................................................... 25 3.5.1 Iron Bioavailability in Caco-2 Cell Monolayers ................ 25 3.5.2 Biocompatibility of porous iron particle ............................ 31 3.6 In vivo study ......................................................... 34 3.6.1 Iron Bioavailability in Iron Deficiency Anemia Rats ........ 34 3.6.2 Iron bioavailability and blood parameters ......................... 36 3.6.2 Acute Oral Toxicity............................................... 37 Chapter 4 Results ......................................................... 39 4.1 Characterization of Porous iron particle ............................... 39 4.2 TEM..................................................................... 40 4.3 DLS .................................................................... 41 4.4 Surface area and porosity ........................................... 42 4.5 Biocompatibility of Porous iron particles .............................. 43 4.6 In Vitro study of Caco-2 model ..................................... 44 4.6.1 Immunocytochemistry Staining of Caco-2 monolayer ...... 44 4.6.2 Effect of ferritin concentration on Caco-2 monolayer ....... 45 4.7 In Vivo study of Rat Hemoglobin Repletion Bioassay ................. 46 4.7.1 Effect of hematology values in iron depletion rats ............ 46 4.7.2 The effects of porous iron particles on iron bioavailability......... 47 4.8 In vivo of oral acute toxicity ........................................ 49 4.8.1 Body weight ................................................... 49 4.8.2 Hematology ....................................................... 50 4.8.3 Serum Biochemical ................................................ 51 4.8.4 Hematoxylin Eosin (H E) Staining ............................. 52 Chapter 5 Discussions ................................................. 54 Chapter 6 Conclusion ................................................... 57 REFERENCES ............................................................. 58 | |
| dc.language.iso | en | |
| dc.subject | 缺鐵性貧血 | zh_TW |
| dc.subject | 多孔鐵粒子 | zh_TW |
| dc.subject | 口服鐵劑 | zh_TW |
| dc.subject | 透析 | zh_TW |
| dc.subject | 血紅素 | zh_TW |
| dc.subject | bioavailability | en |
| dc.subject | hemodialysis | en |
| dc.subject | anemia | en |
| dc.subject | porous iron particles | en |
| dc.subject | hemoglobin | en |
| dc.title | 製備與評估以多孔鐵粒子作為口服鐵劑之研究 | zh_TW |
| dc.title | Preparation and evaluation of porous iron particles as oral iron supplement | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 108-2 | |
| dc.description.degree | 博士 | |
| dc.contributor.oralexamcommittee | 陳克紹(Ko-Shao Chen),吳造中(Chau-Chung WU),郭士民(Shyh-Ming Kuo),陳博洲(Po-Chou Chen) | |
| dc.subject.keyword | 透析,多孔鐵粒子,缺鐵性貧血,口服鐵劑,血紅素, | zh_TW |
| dc.subject.keyword | hemodialysis,anemia,porous iron particles,hemoglobin,bioavailability, | en |
| dc.relation.page | 62 | |
| dc.identifier.doi | 10.6342/NTU202003966 | |
| dc.rights.note | 未授權 | |
| dc.date.accepted | 2020-08-20 | |
| dc.contributor.author-college | 工學院 | zh_TW |
| dc.contributor.author-dept | 醫學工程學研究所 | zh_TW |
| 顯示於系所單位： | 醫學工程學研究所 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| U0001-1808202014042300.pdf 未授權公開取用 | 6.25 MB | Adobe PDF |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。